ROSEN, SENIOR CONSULTANT, Recommends Humacyte, Inc. Dealers. Hedging Advice before the January 17 Securities Class Action Deadline

New York, New York–(Newsfile Corp. – January 4, 2025) – WHY: The Rosen Law Firm, a global investment law firm, reminds clients of Humacyte, Inc.’s securities. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), is relevant. January 17, 2025 is the time to lead the plaintiff.

NOW: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out-of-pocket costs or expenses through a contingency fee arrangement.

WHAT YOU NEED TO DO: To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has been filed. If you wish to act as the lead plaintiff, you must remove the Court before 17 January 2025. The lead plaintiff is the party representing the other members of the class to conduct the case.

WHY ROSE LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Oftentimes, the companies that issue the notices don’t have the experience, the resources, or any meaningful peer recognition. Most of these firms do not litigate securities class actions, but are simply brokers who refer clients or partner with law firms that litigate the cases. Be smart when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder litigation. The Rosen Law Firm achieved the largest defense settlement against a Chinese Company at that time. Rosen Law Firm is ranked No. 1 is the ISS Securities Group Action (WA:) Securities ranking services in 2017. The firm has been ranked 4th every year since 2013 and has earned hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Most of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.

CHARACTERISTICS PRICE: According to the lawsuit, during the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s Durham, North Carolina facility failed to comply and good manufacturing practices, including quality assurance and biological testing. ; (2) the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) would be delayed while Humacyte corrected these deficiencies; and (3) as a result, there was a significant risk of FDA approval of the Acellular Tissue Engineered Vessel (“ATEV”) for vascular infection; and (4) as a result of the foregoing, the defendants’ positive statements about Humacyte’s business, operations, and prospects were materially misleading and/or without a reasonable basis. When the real facts entered the market, the lawsuit alleges that investors were harmed.

To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about a class action.

No Group Guaranteed. Until a group is confirmed, you are not represented by a counselor unless you have reserved one. You can choose a consultant of your choice. You may remain a member of the missing group and do nothing at this point. The investor’s ability to contribute to future recovery does not depend on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: / /www.facebook.com/rosenlawfirm/.

Advertising Attorney. Preliminary results do not guarantee a similar outcome.

——————————

Contact information:

To view the source version of this release, please visit https://www.newsfilecorp.com/release/236071